0
0
India is on the brink of a transformative breakthrough in HIV prevention with plans to domestically manufacture lenacapavir, the world’s first long-acting injectable HIV prevention shot administered twice-yearly. Approved by the US FDA in mid-2025, this injectable option promises to revolutionize HIV prevention globally and particularly in India, thanks to reduced costs and improved adherence potential.
Understanding Lenacapavir: A Twice-Yearly Injection
Lenacapavir, marketed under the brand Yeztugo, is an innovative injectable drug that offers near-complete protection against HIV with just two doses per year. Developed by Gilead Sciences initially for treating multidrug-resistant HIV, lenacapavir is now also approved for pre-exposure prophylaxis (PrEP), aimed at preventing HIV infection before exposure. Its long-lasting effect addresses key barriers associated with daily oral PrEP—namely, adherence difficulties and social stigma linked to daily medication.
Clinical trials have demonstrated lenacapavir’s near-perfect efficacy in preventing new HIV infections, showing almost no infections among participants adhering to the injection schedule. This is a significant advance over the daily pill regimen, which is prone to missed doses, lowering its protective benefits.
Four leading Indian generic drug manufacturers—Dr Reddy’s, Hetero, Emcure, and Mylan—have received royalty-free licenses from Gilead Sciences to produce and supply lenacapavir to 115 low- and middle-income countries, including India. This domestic production is projected to offer the injection at about $40 per person annually— a fraction of the original cost. Such accessible pricing could enable millions to benefit from a powerful preventative tool, especially in resource-constrained settings where HIV remains a public health challenge.
The rollout timeline depends on timely approval by India’s Central Drugs Standard Control Organisation (CDSCO). Experts indicate that the regulatory process for manufacturing approval, plant inspections, and obtaining export certificates could take 1-2 years, potentially targeting commercial launch around 2027. Expedited regulatory pathways and World Health Organization pre-qualification could shorten the wait, accelerating access to this life-saving intervention.
India has achieved important advances in HIV control but still faces challenges with prevention, particularly adherence to daily oral PrEP. Currently, the National AIDS Control Organisation (NACO) endorses condoms as the primary PrEP method. However, public health specialists advocate expanding prevention tools to include lenacapavir, citing its convenience and potential to reduce new infections substantially.
Lenacapavir’s introduction aligns well with goals to reduce HIV incidence by improving accessibility and adherence, especially among high-risk groups. This injectable option removes the burden of daily pill-taking, which can be stigmatizing or logistically difficult for marginalized populations.
Dr. Priya Raman, an infectious disease specialist unaffiliated with the drug’s development, states, “A twice-yearly injectable PrEP is a game-changer. It addresses many adherence challenges of daily pills, with the potential to significantly lower HIV transmission rates if integrated into national programs.” She adds that “rapid regulatory approval and community awareness will be critical to unlocking its full public health impact.”
Ganesh Acharya, an HIV-TB survivor and advocate, echoes this optimism, noting that earlier long-acting therapies were expensive and less accessible. “Lenacapavir offers strength and affordability simultaneously—a combination that can transform lives,” he says.
Despite its promise, lenacapavir’s rollout faces challenges. Cold-chain storage requirements and the need for healthcare infrastructure to administer injections twice a year could limit immediate scalability, particularly in rural or resource-limited areas. Moreover, public education campaigns will be necessary to inform potential users about benefits, administration schedules, and safety.
Additionally, some regulatory experts caution that Indian authorities might require local clinical trials despite existing robust international data, which could delay availability. The inclusion of lenacapavir in India’s national HIV prevention strategies, currently focused on condoms and daily oral PrEP, will require policy updates and budget prioritization.
For individuals at risk of HIV, lenacapavir offers a discreet, low-maintenance prevention option that can fit into varied lifestyles. Replacing the daily pill with two annual injections reduces daily burdens and potentially lowers stigma, fostering higher prevention uptake.
Healthcare providers should counsel eligible patients on this new option once available and ensure that patients understand the necessity of timely injections and follow-up. As with any medical intervention, this should be part of a comprehensive HIV prevention strategy, including safer sex practices and regular health monitoring.
Conclusion
Lenacapavir’s upcoming production in India represents a historic advance in the fight against HIV, with the potential to dramatically reduce new infections through an accessible, effective, and convenient prevention method. If regulatory hurdles are overcome swiftly, India could become a global supplier, enabling broader reach across low- and middle-income countries. With careful implementation, lenacapavir could transform HIV prevention paradigms and save millions of lives worldwide.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
